For example, AML treatment with immunotherapeutic agents that activates T cells, leading to proinflammatory conditions, induces the PD-L1 upregulation in primary AML blasts preventing their lysis as an adaptive immune response–driven resistance mechanism [127]. Here, CD274 is linked to acute myeloid leukemia.